Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
TRACERx Lung: intratumor heterogeneity and clinical outcomes
Lung cancer is the leading cause of cancer-related deaths worldwide, with a five-year relative survival rate of 4% in the metastatic setting. In this issue, three reports from the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) lung study provide insights into tumor evolution and intratumor heterogeneity that may facilitate the development of biomarkers and improve therapeutic outcomes for patients.
Nature Medicine is taking a comprehensive approach for reporting clinical studies with the aim to increase transparency, promote rigorous reporting standards and engage with the community to meet the challenges of contemporary medicine.
Patrícia Brasil is head of the Laboratory of Acute Febrile Illness of the National Institute of Infectious Diseases Evandro Chagas, Fiocruz, and professor of tropical medicine and clinical research in the postgraduate programs of Fiocruz in Rio de Janeiro, Brazil.
As artificial intelligence moves into the realm of clinical trials, consideration is needed on whether the current CONSORT and SPIRIT reporting statements are sufficient to ensure transparency.
Antibodies elicited by the widely deployed rVSV-EBOV Ebola virus vaccine mirror those of disease survivors, animal models and other vaccine platforms. Notably, neutralizing antibodies are consistently elicited from a recurring pair of germline genes.
A novel oral capsule can deploy microneedle patches that release drugs into the intestinal wall for uptake into the bloodstream as shown in animal studies, thereby avoiding injections.
An engineered truncated gene derived from the dystrophin-related protein (utrophin), prevents pathology without an immune response in an animal model of Duchenne muscular dystrophy (DMD) gene therapy.
Single-cell RNA sequencing characterizes clonal dynamics and distinct cellular states contributing to intratumoral heterogeneity in glioblastoma and medulloblastoma.
Rare genetic diseases frequently involve a neuropsychiatric component for which a defined framework of investigation will expedite our understanding for these diseases as a whole.
This first-in-human study assessed the feasibility of vaginal microbiome transplantation from healthy donors as a therapeutic alternative for patients suffering from symptomatic, intractable and recurrent bacterial vaginosis.
A gene therapy vector expressing micro-utrophin provides functional replacement of lost dystrophin, and lacks the adverse immunogenicity associated with direct dystrophin therapy, in rodent and canine models of Duchenne muscular dystrophy.
A luminal unfolding microneedle injector device (LUMI) is engineered as a custom capsule capable of efficient biologic macromolecular drug delivery into the bloodstream via selective deployment within the gastrointestinal tract.
Deep convolutional neural networks predict survival of mesothelioma patients and identify histological features associated with outcome that transcend current histological classifications.
Whole-genome sequencing in triple-negative breast cancer supports the prognostic value of the HRDetect mutational-signature-based algorithm for improving patient stratification in a real-world, population-based clinical diagnostic setting.
TRACERx Lung: Intratumoral transcriptional heterogeneity, which often hinders the development of clinically useful RNA-expression-biased biomarkers for cancer, can now be overcome with an approach for the identification of clonal expression biomarkers.
A survey of T cell repertoire evolution in the tumors, healthy tissue and blood of patients with early-stage untreated lung cancer offers an opportunity to monitor and identify neoantigen-specific T cells for personalized immunotherapy.
A first-in-human, phase 1 dose-escalation trial demonstrates the safety and feasibility of autologous macrophage therapy in adults with liver cirrhosis.
Expansion of human hematopoietic stem cells present in cord blood or bone marrow can be achieved by cell culture in a hydrogel, potentially facilitating clinical applications of hematopoietic cell transplantation.
Single-cell proteomic and transcriptional profiling of atherosclerotic lesions from human carotid arteries reveals specific features of lesional T cells and macrophages associated with symptomatic disease.